Compare GSK Pharma with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs JUBILANT PHARMOVA - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA JUBILANT PHARMOVA GSK PHARMA/
JUBILANT PHARMOVA
 
P/E (TTM) x 50.5 14.3 352.6% View Chart
P/BV x 11.4 2.7 425.9% View Chart
Dividend Yield % 1.4 0.6 249.4%  

Financials

 GSK PHARMA   JUBILANT PHARMOVA
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
JUBILANT PHARMOVA
Mar-19
GSK PHARMA/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs3,595898 400.3%   
Low Rs1,253618 202.9%   
Sales per share (Unadj.) Rs184.7572.0 32.3%  
Earnings per share (Unadj.) Rs26.336.2 72.6%  
Cash flow per share (Unadj.) Rs29.259.5 49.0%  
Dividends per share (Unadj.) Rs20.004.50 444.4%  
Dividend yield (eoy) %0.80.6 138.9%  
Book value per share (Unadj.) Rs126.3301.9 41.8%  
Shares outstanding (eoy) m169.40159.28 106.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.11.3 990.9%   
Avg P/E ratio x92.220.9 440.7%  
P/CF ratio (eoy) x83.112.7 652.8%  
Price / Book Value ratio x19.22.5 764.6%  
Dividend payout %76.112.4 612.4%   
Avg Mkt Cap Rs m410,626120,694 340.2%   
No. of employees `0005.02.4 207.5%   
Total wages/salary Rs m5,37219,260 27.9%   
Avg. sales/employee Rs Th6,306.738,120.6 16.5%   
Avg. wages/employee Rs Th1,083.18,058.4 13.4%   
Avg. net profit/employee Rs Th898.02,414.3 37.2%   
INCOME DATA
Net Sales Rs m31,28191,108 34.3%  
Other income Rs m1,023357 286.3%   
Total revenues Rs m32,30491,466 35.3%   
Gross profit Rs m6,00917,390 34.6%  
Depreciation Rs m4863,709 13.1%   
Interest Rs m62,198 0.3%   
Profit before tax Rs m6,54011,840 55.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m287-2,802 -10.2%   
Tax Rs m2,3733,268 72.6%   
Profit after tax Rs m4,4545,770 77.2%  
Gross profit margin %19.219.1 100.6%  
Effective tax rate %36.327.6 131.5%   
Net profit margin %14.26.3 224.8%  
BALANCE SHEET DATA
Current assets Rs m20,06145,848 43.8%   
Current liabilities Rs m14,54320,897 69.6%   
Net working cap to sales %17.627.4 64.4%  
Current ratio x1.42.2 62.9%  
Inventory Days Days5757 100.0%  
Debtors Days Days1451 27.6%  
Net fixed assets Rs m14,34365,498 21.9%   
Share capital Rs m1,694159 1,063.4%   
"Free" reserves Rs m19,70447,930 41.1%   
Net worth Rs m21,39848,089 44.5%   
Long term debt Rs m242,429 0.0%   
Total assets Rs m39,113114,685 34.1%  
Interest coverage x1,091.06.4 17,082.5%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.80.8 100.7%   
Return on assets %11.46.9 164.1%  
Return on equity %20.812.0 173.5%  
Return on capital %31.912.4 257.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53412,422 4.3%   
Fx outflow Rs m7,09117,227 41.2%   
Net fx Rs m-6,557-4,805 136.5%   
CASH FLOW
From Operations Rs m3,99411,215 35.6%  
From Investments Rs m-1,433-10,118 14.2%  
From Financial Activity Rs m-3,5846,574 -54.5%  
Net Cashflow Rs m-1,0237,612 -13.4%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 50.7 3.5 1,448.6%  
Indian inst/Mut Fund % 10.2 8.7 117.2%  
FIIs % 23.8 21.2 112.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 21.1 73.0%  
Shareholders   102,036 23,815 428.5%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  FRESENIUS KABI ONCO.  DR. REDDYS LAB  ABBOTT INDIA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades On a Volatile Note, Dow Futures Up by 68 Points(12:30 pm)

Share markets in India are presently trading on a volatile note. The BSE Sensex is trading up by 11 points, flat, at 47,960 levels.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Warning About Bubbles(Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Apr 20, 2021 03:16 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS